Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III Biopharmaceutical Report I Issue18_December 2018 Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study o...
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake Biopharmaceutical Report II Issue17_July 2018 Eisai’s (TYO:4523) Lenvima (lenvatinib) has a clear path to approval in first-line hepatoce...
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval Biopharmaceutical Report I Issue17_July 2018 Immunomedics’ (NASDAQ:IMMU) Phase I/ II sacituzumab govitecan hormone receptor positive (HR+...
Shooting for the Universe Biopharmaceutical Report III Issue16_April 2018 SHOOTING FOR THE UNIVERSE By Michael Leviten, Senior Writer CureVac AG is bringing a new ...
Biosimilar Uptake Still Plagued by Interchangeability Hurdles Biopharmaceutical Report II Issue17_July 2018 Biosimilar interchangeability with reference biologics remains a challenge years after prod...
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments Biopharmaceutical Report I Issue16_April 2018 Alnylam’s (NASDAQ:ALNY) trade secrets litigation case against Dicerna (NASDAQ:DRNA) could s...
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica Biopharmaceutical Report II Issue15_November 2017 BeiGene’s (NASDAQ:BGNE) BGB-3111 for Waldenström’s macroglobulinemia (WM) will need lon...
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations Biopharmaceutical Report I Issue15_November 2017 Corbus Pharmaceuticals’ (NASDAQ:CRBP) Phase II study of anabasum in skin-predominant der...
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery Biopharmaceutical Report III Issue14_July 2017 BY EMILY CUKIER-MEISNER, SENIOR WRITER Dong-A ST Co. Ltd. has spent the last four years bu...
Medical Device: Growing Cybersecurity Threat and Need for More Regulation Biopharmaceutical Report II Issue14_July 2017 Despite an expected increase in the frequency in cybersecurity threats in the near future t...
Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC) Biopharmaceutical Report I Issue15_July 2017 • Valuations unreliable given large timeframe to market • Likely EU/US pricing pressures...
Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty Biopharmaceutical Report II Issue13_April 2017 Western-origin chimeric antigen receptor T-cell (CAR-T) therapies being developed in China...
Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance Biopharmaceutical Report I Issue13_April 2017 Proposed legislation across 23 US states to force payers to increase reimbursement of abuse...
Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma Biopharmaceutical Report III Issue12_December 2016 Roche’s (VTX:ROG) Phase III GALLIUM study of Gazyva (obinutuzumab) in first-line folli...
Humira Biosimilar Unlikely to Reach the Market Before 2020 Biopharmaceutical Report II Issue12_December 2016 The numerous biosimilars for AbbVie’s (NYSE:ABBV) Humira (adalimumab) are unlikely ...
